File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Interferon treatment for hepatitis C virus infection in patients on haemodialysis

TitleInterferon treatment for hepatitis C virus infection in patients on haemodialysis
Authors
KeywordsErythropoietin
Haemodialysis
HCV genotype
HCV RNA
Hepatitis C virus (HCV)
Interferon
Issue Date1997
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
Nephrology Dialysis Transplantation, 1997, v. 12 n. 7, p. 1414-1419 How to Cite?
AbstractBackground. This study examined the efficacy and tolerability of interferon α-2b (IFN) in the treatment of chronic hepatitis C virus (HCV) infection in patients on maintenance haemodialysis. Methods. A 24-month prospective cohort study was performed in 11 HCV RNA-positive haemodialysis patients, who were treated with IFN at 3 MU thrice weekly for 6 months. Serial biochemical and virological monitors included serum alanine aminotransferase levels, and HCV RNA by both qualitative PCR assay and quantitative bDNA assay. HCV genotypes were determined by PCR and nucleotide sequencing. Ten patients had baseline liver biopsy. Results. HCV genotypes 1b and 2b were identified in 10 and one patients respectively. Six (55%) patients had biochemical and/or histological features of chronic active hepatitis before treatment. All 11 patients became HCV RNA-negative by PCR, with normalization of deranged aminotransferase levels, within 2-8 weeks of IFN therapy. HCV RNA reappeared in eight (73%) patients 2-8 weeks after the cessation of IFN, while biochemical relapse occurred in six (55%) patients. Sustained eradication of HCV was achieved in three (27%) patients. Sustained responders were characterized by pretreatment HCV RNA level < 3.5 x 105 Eq/ml as determined by the bDNA assay, and less severe histological abnormalities ('Total score' 1.7 ± 1.2 compared to 5.4 ± 2.2 in relapsers, P < 0.05). HCV RNA levels were similar before and after IFN treatment in non-responders and relapsers. Persistent malaise and poor appetite were noted in eight (73%) patients during IFN therapy. Other side-effects of IFN included the exacerbation of anaemia, induction of resistance to erythropoietin, weight loss, and reduced serum albumin level. Conclusions. Eradication of chronic HCV infection with IFN can be achieved in 27% of haemodialysis patients. Predictors of sustained response include low baseline HCV RNA level and mild liver pathology. Virological relapse can occur despite normal liver biochemistry. Exacerbation of anaemia, erythropoietin resistance, and malnutrition constitute the side-effects of IFN that deserve special attention in uraemic subjects.
Persistent Identifierhttp://hdl.handle.net/10722/49065
ISSN
2015 Impact Factor: 4.085
2015 SCImago Journal Rankings: 1.780
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.contributor.authorWu, PCen_HK
dc.contributor.authorLau, JYNen_HK
dc.contributor.authorLok, ASFen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorCheng, IKPen_HK
dc.date.accessioned2008-06-12T06:33:38Z-
dc.date.available2008-06-12T06:33:38Z-
dc.date.issued1997en_HK
dc.identifier.citationNephrology Dialysis Transplantation, 1997, v. 12 n. 7, p. 1414-1419en_HK
dc.identifier.issn0931-0509en_HK
dc.identifier.urihttp://hdl.handle.net/10722/49065-
dc.description.abstractBackground. This study examined the efficacy and tolerability of interferon α-2b (IFN) in the treatment of chronic hepatitis C virus (HCV) infection in patients on maintenance haemodialysis. Methods. A 24-month prospective cohort study was performed in 11 HCV RNA-positive haemodialysis patients, who were treated with IFN at 3 MU thrice weekly for 6 months. Serial biochemical and virological monitors included serum alanine aminotransferase levels, and HCV RNA by both qualitative PCR assay and quantitative bDNA assay. HCV genotypes were determined by PCR and nucleotide sequencing. Ten patients had baseline liver biopsy. Results. HCV genotypes 1b and 2b were identified in 10 and one patients respectively. Six (55%) patients had biochemical and/or histological features of chronic active hepatitis before treatment. All 11 patients became HCV RNA-negative by PCR, with normalization of deranged aminotransferase levels, within 2-8 weeks of IFN therapy. HCV RNA reappeared in eight (73%) patients 2-8 weeks after the cessation of IFN, while biochemical relapse occurred in six (55%) patients. Sustained eradication of HCV was achieved in three (27%) patients. Sustained responders were characterized by pretreatment HCV RNA level < 3.5 x 105 Eq/ml as determined by the bDNA assay, and less severe histological abnormalities ('Total score' 1.7 ± 1.2 compared to 5.4 ± 2.2 in relapsers, P < 0.05). HCV RNA levels were similar before and after IFN treatment in non-responders and relapsers. Persistent malaise and poor appetite were noted in eight (73%) patients during IFN therapy. Other side-effects of IFN included the exacerbation of anaemia, induction of resistance to erythropoietin, weight loss, and reduced serum albumin level. Conclusions. Eradication of chronic HCV infection with IFN can be achieved in 27% of haemodialysis patients. Predictors of sustained response include low baseline HCV RNA level and mild liver pathology. Virological relapse can occur despite normal liver biochemistry. Exacerbation of anaemia, erythropoietin resistance, and malnutrition constitute the side-effects of IFN that deserve special attention in uraemic subjects.en_HK
dc.format.extent418 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/en_HK
dc.relation.ispartofNephrology Dialysis Transplantationen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectErythropoietinen_HK
dc.subjectHaemodialysisen_HK
dc.subjectHCV genotypeen_HK
dc.subjectHCV RNAen_HK
dc.subjectHepatitis C virus (HCV)en_HK
dc.subjectInterferonen_HK
dc.titleInterferon treatment for hepatitis C virus infection in patients on haemodialysisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0931-0509&volume=12&issue=7&spage=1414&epage=1419&date=1997&atitle=Interferon+treatment+for+hepatitis+C+virus+infection+in+patients+on+haemodialysisen_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1093/ndt/12.7.1414en_HK
dc.identifier.pmid9249778-
dc.identifier.scopuseid_2-s2.0-0030836459en_HK
dc.identifier.hkuros27128-
dc.identifier.hkuros31519-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030836459&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume12en_HK
dc.identifier.issue7en_HK
dc.identifier.spage1414en_HK
dc.identifier.epage1419en_HK
dc.identifier.isiWOS:A1997XL49300020-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridWu, PC=7403119323en_HK
dc.identifier.scopusauthoridLau, JYN=7402446047en_HK
dc.identifier.scopusauthoridLok, ASF=35379868500en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridCheng, IKP=7102537483en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats